Effect of Id1 knockdown on formation of osteolytic bone lesions by prostate cancer PC3 cells in vivo.
The formation of osteolytic bone lesions is a key process for osteolytic cancer to metastasize to the bone and is under the control of a set of transcription factors. Recently, the inhibitor of differentiation 1 (Id1) has been linked with angiogenesis, tumorigenesis, metastasis and bone formation. However, the function of Id1 during the process of bone destruction caused by cancer in vivo has not yet been elucidated. We, therefore, examined whether and how Id1 affects the ability of cancer to form osteolytic lesion in vivo. The study used a lentiviral vector overexpressing short hairpin RNA (shRNA) targeting Id1 gene. PC3 cells, a prostate cancer cell line, were transduced with Id1 shRNA or negative control (NC) shRNA before implantation in BALB/c mice. Cells were implanted in a tibial injection model. Tumor formation in bone was monitored by X-ray. The relationship between parathyroid hormone-related protein (PTHrP), an osteolytic factor, and Id1 was analyzed by using immunohistochemistry in tissue sections from osteolytic lesion of the BALB/c mice. Our results showed that Id1 shRNA delivery to PC3 cells by lentivirus caused efficient and stable Id1 gene silencing. In the intratibial model, PC3 cells produced primarily osteolytic lesions in the bone. Eleven of 14 mice in Id1 shRNA group but only 4 of 14 mice in the NC shRNA group developed osteolytic lesions with cortical destruction at 4th week. Mice treated with Id1 shRNA had larger tumor volume in the bone and larger cortical destruction. The expression of PTHrP protein in PC3 cells was not affected by Id1 knockdown in vivo. These results indicate that Id1 may down-regulate the ability of PC3 cells to form osteolytic lesions in vivo and the signal pathway needs to be further investigated.
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zhengguo
Z
Zhang
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.|Department of Orthopaedics, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, 832008, China.
Kuanxin
K
Li
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiaomei
X
Zhang
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zhong
Z
Fang
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.
Wei
W
Xiong
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.
Qi
Q
Chen
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China.
Wenjian
W
Chen
Department of Orthopaedics, Huazhong University of Science and Technology, Wuhan, 430030, China. lifengtongjiys@yahoo.cn.
Feng
F
Li
D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000556:secondary*; D045744:Cell Line, Tumor; D020868:Gene Silencing; D006801:Humans; D051798:Inhibitor of Differentiation Protein 1 / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010014:Osteolysis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*
C497453:ID1 protein, human; D051798:Inhibitor of Differentiation Protein 1